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Abstract 
Background. Australian Aboriginal people living in remote regions have extraordinary higher rates 
of mortality compared to  other Australian ethnicities. Albuminuria marks the underlying renal 
disease. This study assessed the predictive value of albuminuria for nonrenal and renal death in a 
remote Australian Aboriginal community over follow-up of more than 14 years.  
Methods. From 1992-1997, 85% of community members participated in a health screen, which 
included measurement of urine albumin/creatinine (ACR) levels.  Deaths and dialysis starts were 
recorded until 30 November 2010. Rates of natural nonrenal and renal death were assessed over 
a mean of 14 years in the 956 participants aged 18 years and over at baseline, and mortality 
associated with baseline levels of albuminuria (ACR >2.7 mg/mmol) was estimated.   
Results. There were 203 natural deaths; 70 were renal deaths and 133 were nonrenal deaths, 
including 60 CVD deaths. Higher baseline ACR predicted all categories of natural death, with no 
apparent lower threshold for effect.  Baseline ACR >2.7 mg/mmol  predicted a 3.3-fold increase in 
all natural death, a 2-fold increase in nonrenal death, and 1.7-fold increase in CVD deaths, after 
adjustment for other factors. Eighty-nine percent (62 out of 70) of renal deaths occurred in those 
with ACR >34 at baseline, with a 24-fold increase in risk. Albuminuria (ACR >2.7 mg/mmol) 
contributed to 66% of risk for all natural death over the interval.  
Conclusions.  Albuminuria was still a remarkable predictor for all –causes natural death over an 
average 14 years follow up interval in this Aboriginal community.  
 
Abstract word count: 247 
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Short summary: We assessed the predictive value of albuminuria for mortality in a remote 
Australian Aboriginal community over follow-up of more than 14 years. Albuminuria was still a 
remarkable predictor for natural mortality over such a long-term period.  
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Introduction 
Australian Aboriginal people, especially those living in remote regions, have higher rates of all–
cause mortality, of cardiovascular deaths and of end-stage renal disease (ESRD), 1,2 compared to 
other Australian ethnicities. The disparities are worse for younger age groups. Adult Aborigines in 
the Northern Territory have mortality rates two to four times higher than non-Aboriginal 
Australians, while the death rates of 25 to 44 years olds are increased approximately 15–fold.3  
 
The incidence of ESRD among Aborigines living in remote regions is increased up to 30 times the 
national incidence for all Australians.4,5  The high number of renal deaths and nonrenal deaths for 
Aboriginal people are by no means explained solely by diabetes and its co-morbidities. 6, 7 
Albuminuria marks the underlying renal disease.  In a study of one high-risk community, we 
showed that albuminuria, which was pervasive, not only marked all the future risk for renal deaths, 
but also predicted cardiovascular and non-renal non-cardiovascular deaths. 8-10  In that study, 825 
adults, of a mean age of 33.6 years, were followed for a total of 4778 person years and average of 
5.8 years; they experienced 64 natural death endpoints: of which 16 were renal and 36 were 
cardiovascular. Albuminuria (ACR 3.4 mg/mmol and above) was estimated to contribute to all the 
renal deaths and 75% of the risk for nonrenal natural deaths over that interval. 1 Studies in other 
populations and ethnic groups have also documented the association of albuminuria with non-
renal death particularly CVD mortality as well with renal disease and renal death. 6, 10, 11 In one 
study of people aged 55 years and over, the exacerbation of risk for CVD started at a very low 
level of ACR. 12A collaborative meta-analysis indicated that ACR 1.1 mg/mmol or more is an 
independent predictor of mortality risk in the general population. 13 
 
A screening and treatment program for renal disease and hypertension was started in this 
community in Nov 1995 and was conducted with some vigour through mid 1999.  It was 
associated with significant reduction of mortality in treated persons compared with historical 
controls matched for disease severity. 8   With a change in health service administration the 
intervention faltered for a time, but in recent years has been taken up again, with protocols of 
systematic surveillance and treatment now embedded within primary care, although resources 
limit their optimal application.  In a repeat community screen from 2004-2006, 30.4% adults 
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overall, and 52% of those of 50 years and over had prescriptions for antihypertensive agents 
(usually perindopril) and 18.1% overall, and 34% of those age 50 years and over had prescriptions 
for hypoglycaemic agents. 14This was the first Aboriginal community in which the effects of 
angiotensin converting enzyme inhibition in delaying renal and nonrenal deaths in people with 
albuminuria and hypertension were demonstrated. 8, 15  This has subsequently become standard 
practice in all remote Aboriginal health services, and has contributed to the reduction in 
Indigenous death rates in the Northern Territory 21 and nation-wide.5,16 
 
We now describe terminal events in this cohort through a follow up of up to over 14 years in order 
to: define whether albuminuria remains a significant predictor of mortality over the longer period;  
- examine possible relationships with ACR over a continuum; and probe for the predictive value of 
ACR below traditional cut-off point for microalbuminuria.    
 
Subjects and methods 
Subjects were adults in a remote Aboriginal community who participated in the baseline health 
survey between 1992 and 1997 at ages ranging from 18-76 years. The profiles of this community 
have been described previously 6   . Minimum data for inclusion of 956 subjects were age, sex and 
urine ACR.  The sample size was somewhat smaller when covariates such as weight, height, 
blood pressure, lipoprotein and blood glucose were included in analyses. 
All natural deaths were documented until 30 November 2010, as recorded in community and 
hospital records. All death files were confirmed in the local Catholic Church Burial Records.  
Natural deaths were categorized by their primary or underlying cause, into renal, non-renal natural 
death and cardiovascular death, as described previously. 17 Renal death refers to participants who 
started dialysis for ESRD or who died with terminal renal failure without dialysis. The survival time 
of people who died of nonnatural deaths, which included acute intoxications, accidents, drowning, 
suicide and homicide, was documented: they were censored from the analysis at time of death, 
and their deaths were not included in this analysis.  
Height, weight, blood pressure and levels of glycemia were measured using standard procedures.  
Some diagnostic criteria used in this study were as follows:  
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- Diabetes: known to be diabetic before the survey and/or  with fasting glucose ≥7.0 mmol/L) (≥ 
126.1 mg/dl) or 2-hr glucose or random glucose level ≥ 11.1 mmol/L (200 mg/dl) at testing.  
- Obesity : BMI ≥ 30 kg/m2 
- Hypertension: SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg   
Urine albumin concentrations were measured simultaneously by both nephelometric and HPLC 
techniques on baseline random urine samples after retrieval from -70oC storage.  When examined 
over a Z score continuum of their values, they were identical in defining clinical profiles and 
predicting death.20 Results here are based on ACR levels derived from albumin measured by 
immunonephelometry (Beckman Instruments, Brea, CA), and from urinary creatinine 
concentration measured using the modified kinetic Jaffe reaction (Olympus AU600 Autoanalyzer; 
inter-assay CV 2%).  As the median value of ACR of this cohort was 2.7 mg/mmol, which is lower 
than the conventional microalbuminuria cut-off point, albuminuria was arbitrarily defined as urine 
ACR≥2.7mg/mmol in this study, while the conventional threshold of ACR ≥34 mg/mol was defined 
as overt proteinuria.   
Quartiles of ACR level and log-transformed (log base 2) ACR were applied in the analyses. 
Baseline characteristics across progressive quartiles of ACR were compared. Cox regression 
analyses were employed to calculate hazard ratios (95% CI) of all natural death, renal, nonrenal 
and CVD death predicted by ACR, and to allow adjustment for age, sex and other covariates.  The 
Kaplan-Meier method was used to estimate fractional survivals according to different baseline 
ACR levels.  The population attributable fraction (PAF) of mortality predicted by the presence of 
ACR≥2.7 (mg/mmol) at baseline was calculated using poisson regression adjusted for age, sex 
and time of follow up year. All analyses were undertaken using Stata 11.1 (Stata Corp. Stata 
Statistical Software: Release 11.1, College Station. TX: StataCorp LP, 2009). Statistical 
significance was defined at the level of p <0.05 (two-tailed).   
This study was approved by the Ethics Committee of the Menzies School of Health Research and 
Territory Health Services and The Behavioural and Social Science Ethical Review Committee of 
the University of Queensland. 
 
Results 
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Those 956 participants were followed for a total of 13,714 years, a range of 0 to 18 years, and a 
median and mean of 16 and 14 years respectively. ACR ranged 0-675.5 (mg/mmol) with median 
value of 2.7 (mg/mmol). Their characteristics by baseline quartiles of ACR are shown in Table1. 
Age was progressively higher with higher ACR quartiles, and levels of cholesterol and triglycerides, 
and the percentage with obesity, hypertension and diabetes was also higher, either across quartiles 
on a continuum or with level above the ACR median. Those in the highest quartile were more often 
female.  
 
A total of 203 natural deaths were documented while 37 people died of misadventure (nonnatural 
deaths).The natural deaths included 70 renal deaths and 133 nonrenal deaths of which 60 were 
CVD deaths. Table 2 shows deaths by gender: numbers and rates of renal deaths were more 
common in females, but there was no gender difference in other categories of death.  
 
Table 3 shows the numbers and rates of natural death by quartile of baseline ACR level.  The 
incidence of all natural death, non-renal and CVD death rose significantly with increasing ACR 
quartiles.  However all renal deaths were confined to people in quartiles 3 and 4 of baseline ACR 
levels, i.e., ACR ≥ 2.7 mg/mmol. Figures 1A, 1B and 1C show the Kaplan-Meier survival curves for 
all natural death, for renal and for nonrenal death by baseline ACR quartiles. After 14 years, only 
51.4% of people in the highest baseline ACR quartile had avoided all natural death:  70.3% had 
avoided renal death and 73.1% had avoided nonrenal deaths. The survival curve of renal death for 
people within the category of the highest ACR quartile was significantly different from people in 
lower ACR quartile, and so was for nonrenal death. 
 
Table 4 lists HRs (95% CI) of different end-points according to quartiles of baseline ACR and 
log-transformed (base 2) ACR.  The risks of all natural death and of non-renal death rose with 
increasing ACR quartiles, and with each doubling of ACR, with similar levels of risk 
exacerbation for females and males. For example, the HRs (95%CI) of log-transformed (base 
2) ACR for all natural death were 1.4 (1.3-1.6) for females, 1.3 (1.1-1.4) for males; and the 
HRs for non-renal death were 1.2 (1.0-1.3) for females and 1.1 (1.0-1.3) for males. Compared 
to those with the first ACR quartile, the risks of CVD death were significantly and comparably 
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raised in those with ACR in the second and third quartiles, and strikingly elevated in those in 
the highest ACR quartiles. The trends persisted with adjustment for age, sex and other 
factors, including blood pressures and glucose levels (Table 4). 
Figure 2 shows predicted renal and nonrenal death by log-transformed (based 2) ACR for 
people aged 18 years and over. The statistical significance between two curves has been 
calculated by comparing their ROC curves. It indicated that the ROC curve for renal death 
predicted by ACR is significantly larger than for non-renal death. The rate of increase of 
predictions of non-renal death rate speeds up at ACR level less than 3.4 mg/mmol, while the 
threshold for renal death was at a higher ACR level (figure 2). Table 5 shows people with 
ACR ≥2.7 (mg/mmol) (the group median) predicted 3.3-fold increase in all natural death, and 
2.2-fold and 1.9-fold increases in non-renal deaths and CVD deaths respectively relative to 
the people with ACR <2.7 after adjusting for sex and age.  As no renal deaths occurred in 
those with ACR <2.7/mg/mmol) (Table 5), the HR of ACR ≥2.7 vs.<2.7 could not be 
calculated (Table 5).  However, eighty-nine percent (62 out of 70) of renal deaths occurred in 
those with ACR >34 at baseline, with HR (95%CI) of 23.8 (8.0-71.2) for females and 23.7 
(4.1-135.0) for males after adjustment for a number of risk factors . It also shows that the 
population attributable fraction of natural deaths associated with ACR levels at or above the 
median value of 2.7 mg/mmol was 66% for all natural death, 45% for nonrenal deaths and 
34% for CVD death (Table 5).  
When analysed around the “traditional” microalbuminuria cut-off of ACR ≥ 3.4 mg/mmol, the 
PAFs were 64% for all natural death, 41% for nonrenal death and 32% for CVD death. These 
compare with those of 84%, 65% and 75% those categories of deaths calculated by Hoy et al 
in the first five years of the observation in people before systematic treatment was initiated. 6 
Discussion 
In this community, albuminuria (ACR≥2.7mg/mmol) predicted nonrenal death while overt 
proteinuria (ACR ≥34 mg/mmol) predicted renal death over an average 14 years follow up 
(median  follow up of 16 years). This confirms our previous observation of the predictive value 
of albuminuria for natural death over a much shorter interval in people who were followed 
without or before the introduction of systematic treatment.8 The relationship still applies, over 
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almost 3-fold increase in average duration of follow up, almost three times the number of 
person years follow up, and more than 3 times the number of deaths.  Among these deaths, 
the number of renal deaths was increased more than 3-fold, and of CVD deaths more than 
doubled.   Despite advancing age, the mortality of those without pathologic albuminuria at 
baseline remains small, and that those with the highest baseline levels continue to do worse 
even after 10-15 years. 
The relationships also remained strong against a changing background of events, which 
include a fluctuating level of surveillance and treatment, and against a background of falling 
mortality rates overall. Falling mortality rates, which  were first detected after introduction of 
systematic treatment, are now evident from overall community deaths and census data,  and 
were echoed in falling mortality rates in remote Australian Aboriginal people more generally 
(report in preparation), 
To our knowledge this is the longest follow up study of the predictive values of albuminuria 
over natural death although many population-based studies in this subject have been 
published in last decades.13,18-26  For example, Drury et al reported that reduced eGFR and 
albuminuria are independent risk factors for CVD events and mortality rate in a 5-year follow 
up diabetic cohort. 22  In a 12.9- year follow-up for the cohort of 1,113 elderly men, urinary 
albumin excretion rate (UAER) and eGFR increased risk for CVD death. 24 
The population attributable fractions calculations suggest that 66% of all natural deaths 
including 100% of renal deaths and 45% of nonrenal death would have been avoided if 
baseline ACR levels had been uniformly less than the population median of 2.7 mg/mmol. 
Alternatively, with all baseline levels <3.4 mg/mmol, the “traditional” microalbuminuria 
threshold, the avoided proportions would have been 64% for all natural death, 100% for renal 
death and 41% for nonrenal death respectively.     
The substantial reduction in population attributable fractions of ACR ≥3.4 for all natural death 
and nonrenal death over the longer follow up in relation to that in our first report is probably 
due to culling of people at highest risk for death from the cohort in the early years, as well as 
mitigation of outcomes due to more systematic treatment of those with disease. This should 
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also have improved the outcomes in people who were “normal” at baseline, who subsequently 
developed overt albuminuria or hypertension, if they were detected and treated. Despite 
these considerations, albuminuria remained a powerful predictor of all-cause natural death 
over a 14-year period. These provide powerful arguments for unflagging efforts to prevent the 
development of pathologic levels of albuminuria and to reduce its progression.   
In our study the predictions of renal death by baseline ACR levels were incontrovertible, but 
with a threshold level of baseline ACR that was clearly already abnormal (i.e., ACR≥2.7 
mg/mmol). However, it also showed prediction of nonrenal death by baseline ACR levels 
starting below the traditional microalbuminuria cut-off (3.4mg/mmol). This supports the 2001 
report of Gerstein et al in a group subjects aged 55 years or more, with or without diabetes in 
the context of cardiovascular risk prediction. 12 The potential explanations of these important 
associations remain speculative.    
In this study, estimated GFR (MDRD formula, without adjustment for race) was also a 
significant predictor for renal deaths in the presence of other factors, including ACR. 
However, the predictive value of the terminal outcome by ACR was not much affected by 
adding GFR in the modelling. Previous reports also suggested that the predictive value of 
microalbuminuria on mortality is independent of eGFR,  27 and albuminuria and eGFR were 
multiplicatively associated with all –cause mortality without evidence for interaction.  13 , 21, 26  
The rates of renal death in this Aboriginal cohort are astounding compared with those in 
Western populations. Females had a significantly higher renal death rate than males, which is 
also seen in other remote Aboriginal populations.  14 This is consistent with the higher 
prevalence of albuminuria in females than in males, which in turn might be related to their 
lower birthweights and higher rates of diabetes, as well as their failure to show usual female-
related relative protection from childhood poststreptococcal glomerulonephritis, 6, 14, 28, 29 
  
Strengths of this study are more than 80% community participation in the baseline screen, the 
excellent ascertainment of outcomes and the long duration of follow up.  Potential 
weaknesses include the fact that only one baseline random urine sample was taken and that 
 10 
ACR was not confirmed with a morning urine sample, and  the necessary “lumping” of 
categories of death into mutually exclusive categories by primary or underlying cause, 
whereas most natural deaths actually had more than one underlying morbid or contribution 
condition.  However, demonstration of the relationship of albuminuria to the distinct and 
accurate category of all-cause natural death is clear.  Furthermore, the main predictions are 
unchanged when death are grouped by both underlying and associated causes.  The 
changing background of underlying health profiles and of disease management in the follow 
up period poses an additional challenge to mechanistic interpretation, but it represents the 
real world of health service delivery, against which the phenomenon described here remains 
very powerful. Finally, nearly one third of the variances for all natural death remain 
unexplained by these simplistic models. We anticipate that these findings will apply to other 
remote Aboriginal communities with similar renal failure and mortality profiles. 5  However they 
need to be tested in the context of less remote-living Indigenous Australians, who have lower 
rates of both nonrenal and renal death.  
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Table 1 Characteristics of participants aged 18 years and over with ACR quartiles   
 ACR quartile 1 ACR quartile 2 ACR quartile 3 ACR quartile 4 p value  
Characteristics  (ACR range 0-0.6) (ACR range 0.7-2.7)  (ACR range 2.7-19.5)  (ACR range 19.6-675.5)   
Female % 40.8 50.6 46.8 59.2 0.001 
Age (year) 30.2 (10.4) 32.3 (11.5) 35.0 (11.8) 42.0 (12.1) <0.001 
Total cholesterol (mmol/L) 4.37 (1.01) 4.51 (1.01) 4.71 (1.05) 5.21 (1.28) <0.001   
HDL cholesterol (mmol/L) 1.15 (0.33) 1.14 (0.28) 1.10 (0.25) 1.06 (0.23) 0.0064 
Triglyceride (mmol/L)                1.64 (1.29) 1.84 (1.25) 2.14 (1.24) 3.12 (2.68) <0.001    
Obesity% 8.4 (4.9-12.0) 7.6 (4.2-11.0) 16.2 (11.4-20.9) 24.6 (19.0-30.1) <0.001    
Hypertension% 13.5 (9.1-17.9) 14.7 (10.1-19.3) 23.9 (18.4-29.4) 41.7 (35.4-48.1) <0.001 
Diabetes %   2.5 (0.5-4.5) 7.1 (3.8-10.3) 10.6 (6.7-14.5) 31.8 (25.9-37.7) <0.001    
Notes: data were mean (SD) for continuous variables and percentage (95% CI) for categorical variables  
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      Table 2 Natural death by sex for Tiwi people aged 18 years and over   
 Men  Women  All  P value 
Number of participants 485 471 956 
 
 
 
 
Follow-up years                       6,930 6,785 13,714  
All natural death      
Number  100 103 203  
Incidence  14.4 (11.8-17.5) 15.2 (12.4-18.4) 14.8 (12.8-17.0) 0.7159 
Renal death      
Number 26 44 70  
Incidence 3.8 (2.5-5.5) 6.5 (4.7-8.7) 5.1 (4.0-6.4) 0.0247 
Non-renal death      
Number  74 59   133  
Incidence  10.7 (8.4-13.4) 8.7 (6.6-11.2)              9.7 (8.1-11.5) 0.2362 
 
 
CVD death      
Number 35 25 60  
Incidence  5.1 (3.5-7.0) 3.7 (2.4-5.4) 4.4 (3.3-5.6) 0.2256 
Notes: p value refers to comparison between men and women; Incidence refers to death per 1,000 person years (95% CI);  
 
 
Table 3 Natural death by ACR quartile for Tiwi people aged 18 years and over   
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 P trend  
ACR range (mg/mmol) 0-0.6 0.7-2.7 2.72-19.6 20.2-675.5  
Number of participants 240 241 236 239  
Follow-up years                       3,766 3,736 3,465 2,749  
All natural death       
Number  11 25 42 125  
Incidence  2.9 (1.5-5.2) 6.7 (4.3-9.9) 12.1 (8.7-16.3) 45.5 (38.0-53.9) <0.001 
Renal death       
Number 0 0 5 65  
Incidence   1.4 (0.5-3.4) 23.6 (18.3-33.3) <0.001 
Non-renal death       
Number  11 25 37   60  
Incidence  2.9 (1.5-5.2)      6.7 (4.3-9.9) 10.7 (7.5-14.7) 21.8 (16.7-28.1) <0.001 
 CVD death       
Number 4 15 11 30  
Incidence  1.1 (0.3-2.7) 4.0 (2.2-6.6) 3.2 (1.6-5.7) 10.9 (7.4-15.5) <0.001 
Notes: Incidence as per 1,000 person years (95% CI);   
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           Table 4 Hazard ratios (95% CI) of outcomes by ACR quartile and log-transformed (base 2) ACR  
                             ACR quartiles    
 1          2                   3                    4 P  trend   Log 2ACR 
ACR range (mg/mmol) 0-0.6 0.7-2.7 2.72-19.6 20.2-675.5  0-675.5 
All natural death        
Crude HR (95% CI)    1.0 2.3 (1.1-4.7) 4.2 (2.1-8.1) 15.7 (8.5-29.1) <0.001 1.4 (1.4-1.5) 
HR1 (95% CI) 1.0 2.0 (1.0-4.2) 3.3 (1.7-6.5) 9.5 (5.1-17.6) <0.001 1.3 (1.3-1.4) 
HR2 (95% CI) 1.0  1.5 (0.7-3.3) 2.6 (1.3-5.4) 6.2 (3.1-12.4) <0.001 1.3 (1.2-1.4) 
 
HR3 (95% CI) 1.0 1.7 (0.7-3.9). 3.2 (1.5-7.0) 7.8 (3.7-16.6) <0.001 1.4 (1.3-1.5) 
HR4 (95% CI) 1.0  1.4 (0.6-3.0)  2.5 (1.2-5.1) 5.9 (3.0-11.9) <0.001 1.3 (1.2-1.4) 
 
HR5 (95% CI) 1.0  1.0 (0.4-2.5)      2.2 (1.0-4.7) 5.1 (2.4-10.6) <0.001 1.3 (1.2-1.4) 
Renal death*         
Crude HR (95% CI)                  2.4 (2.0-2.8) 
HR1 (95% CI)      2.4 (2.0-2.8) 
HR2 (95% CI)      2.7 (2.1-3.4) 
HR3 (95% CI)      2.8 (2.3-3.6) 
HR4 (95% CI)      2.7 (2.1-3.4) 
HR5 (95% CI)      3.0 (2.2-4.0) 
Non-renal death        
Crude HR(95% CI)     1.0  2.3 (1.1-4.7)   3.7 (1.9-7.2) 7.5 (3.9-14.2) <0.001 1.2 (1.2-1.3) 
HR1 (95% CI) 1.0 2.0 (1.0-4.1) 2.8 (1.4-5.5) 4.0 (2.1-7.8) <0.001 1.1 (1.1-1.2) 
HR2 (95% CI) 1.0 1.5 (0.7-3.2) 2.3 (1.1-4.7) 2.9 (1.4-6.1) 0.001 1.1 (1.0-1.2) 
 
HR3 (95% CI) 1.0  1.6 (0.7-3.8) 2.7 (1.2-6.0) 3.3 (1.5-7.4) 0.001 1.1 (1.1-1.3) 
HR4 (95% CI) 1.0  1.2 (0.5-2.7) 1.9 (0.9-3.9) 2.4 (1.1-5.2) 0.006 1.1 (1.0-1.2) 
HR5 (95% CI) 1.0 1.1 (0.5-2.9)  1.9 (0.9-4.2) 2.2 (1.0-4.9) 0.023 1.1 (1.0-2.2) 
CVD death        
Crude HR (95% CI)    1.0  3.8 (1.3-11.4) 
 
3.0 (1.0-9.4) 10.1 (3.5-28.7) <0.001 1.2 (1.1-1.4) 
HR1 (95% CI) 1.0 3.5 (1.1-10.4) 2.4 (0.8-7.6)  6.1 (2.1-17.7) 0.001 1.2 (1.1-1.3) 
HR2 (95% CI) 1.0 2.5 (0.8-8.0) 1.9 (0.6-6.0) 3.7 (1.2-11.5) 0.033 1.1 (1.0-1.3) 
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HR3 (95% CI) 1.0          3.4 (0.9-12.5) 2.6 (0.7-9.7) 4.8 (1.3-17.0)  0.023 1.1 (1.0-1.3)  
HR4 (95% CI) 1.0 2.2 (0.7-7.0) 1.6 (0.5-5.1) 3.2 (10-10.0) 0.067 1.1 (1.0-1.3) 
HR5 (95% CI) 1.0 2.1 (0.6-7.2) 1.5 (0.5-5.1) 2.7 (0.8-8.6) 0.135 1.1 (1.0-1.3) 
 Notes: * the HR of renal death by log-transformed ACR; HR 1 adjusted for sex and age; HR 2 adjusted for sex, age, diabetes, hypertension, obesity, total cholesterol, HDL and triglycerides ; HR 3 adjusted for sex, age, systolic blood pressure, 
plasma glucose, obesity, total cholesterol, HDL and triglycerides; HR 4 adjusted for sex, age, diabetes, hypertension, obesity, smoker,  total cholesterol, HDL and triglycerides;  HR 5  adjusted for sex, age, diabetes, hypertension, obesity, CRP,  
total cholesterol, HDL and triglycerides;   
   
 
 
Table 5 Risk of mortality by ACR ≥2.7 and PAF for Tiwi people aged 18 years and over        
   ACR <2.7                                           ACR ≥ 2.7               PAF(95%CI)** 
 events HR  events Crude HR (95% CI)  HR1 (95% CI) HR 2(95% CI)  
All natural death 34 1.0 169 5.9 (4.1-8.5) 4.3 (2.9-6.2) 3.3 (2.1-5.2) 0.66 (0.53-0.75) 
Renal death*  0 1.0 70 See notes See notes See notes 1.00 
 
Non-renal death  34 1.0 99 3.4 (2.3-5.1) 2.4 (1.6-3.5) 2.1 (1.3-3.4) 0.45 (0.26-0.60) 
CVD death 18 1.0 42 2.7 (1.6-4.7) 2.0 (1.1-3.4) 1.7 (0.8-3.3) 0.34 (0.01-0.57) 
 Notes: HR1 adjusted for sex and age; HR 2 adjusted for sex, age, diabetes, hypertension, obesity, total cholesterol, HDL and triglycerides;  * HR of renal death for ACR≥ 2.7 vs.<2.7 could not be calculated because of no events in reference 
group; ** Population attributable fraction of death predicted by ACR ≥ 2.7mg/mmol & adjusted for age, sex and time of follow-up                
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   Figure 1A Survival of all natural death                             Figure 1B Survival of renal death                                    Figure 1C Survival of nonrenal death 
   by baseline ACR quartiles.                                               by baseline ACR quartiles                                               by baseline ACR quartiles 
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        Figure 2 Predicted renal and nonrenal death rate (100 person years) by ACR   
Notes:  the two etched lines stand for actual ACR values= 3.4 and 34 mg/mmol, respectively; 
 
 
 
 
 
